EmCyte Corporation has announced the acquisition of all of the assets of Cellmedix Holdings, including the Centrepid Platelet Concentrator system.
EmCyte Acquires Cellmedix Holdings
1 min read Premium comments
#plateletrichplasmaSecondary#emcytecorporation#progenitorstemcellbiologics
EmCyte Corporation (EmCyte) is a world leader in platelet rich plasma (PRP) and progenitor stem cell biologics. EmCyte’s acquisition of Cellmedix Holdings LLC’s (Cellmedix) assets greatly expands its intellectual property profile and product development capabilities.
With this acquisition EmCyte added the following patent numbers to its portfolio: US 7,829,022 B1; US 9,718,003 B1; and US 10,040,064. EmCyte also added 510(k) BK130079 to its intellectual property portfolio.
According to the press release: “This intellectual property additions intensify EmCyte’s innovative capabilities and expand its pathway for forward-thinking biologic creativity. Additionally, it improves EmCyte’s ability to protect the technology it provides to its distributors and end users as it continues to facilitate remarkable clinical outcomes for its patients.”
“We’re thrilled about the acquisition of Cellmedix Holdings,” Patrick Pennie, EmCyte CEO and founder, told OTW. “The acquisition of the Centrepid Platelet Concentrator will expand our intellectual portfolio and strengthen our product line, which translates to a more effective deliverable for our patients.”
Pennie emphasized, “EmCyte is committed to quality outcomes and we are interested in technology and innovation that allows us to continue to develop products that truly make a difference in the lives of our patients.”
EmCyte’s goal is to “provide the most powerful and effective autologous regenerative biologics.” The company prides itself on responding to the needs of regenerative medicine practicioners and medical providers. EmCyte collaborates with industry key opinion leaders to develop innovative treatments that are designed to enhance clinical outcomes and the patient experience.
Fort Myers, Florida-based EmCyte is a global leader in PRP and progenitor stem cell biologics. Since its founding in 1999, EmCyte has prided itself on developing “products that meet the highest achievable performance standard”. EmCyte is also a provider of advanced clinical and scientific training and support through its educational division, Gulf Coast Biologics, Inc.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.